Literature DB >> 22011437

Phenotypic differences between familial versus sporadic ankylosing spondylitis: a cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER).

Raquel Almodóvar1, Pilar Font, Pedro Zarco-Montejo, Eduardo Collantes, Juan Mulero, Jordi Gratacós, Xavier Juanola, Rafael Ariza.   

Abstract

OBJECTIVES: To analyse potential differences in disease phenotype between patients with familial ankylosing spondylitis (AS) and sporadic AS.
METHODS: A cross-sectional study was conducted on all patients with definite AS registered at the internet database REGISPONSER. Sociodemographic data, clinical features, spinal mobility measurements, the Bath AS disease activity index (BASDAI), functional index (BASFI) and radiology index (BASRI), laboratory data (ESR, CRP, HLA-B27), overall patient assessment of the disease (VAS), and treatments used were obtained. Familial AS was considered when the patient was confirmed to have first-degree relatives with spondyloarthropathy. The Chi-square test and Mann-Whitney U-test were used for the statistical analysis.
RESULTS: A total of 1316 AS patients (990 males, 326 females; mean age 48.2 ± 12.6 years), with mean age at symptom onset 26.1 ± 8.5 years, were evaluated. The prevalence of familial AS was 20% (n=263). Familial and sporadic AS groups presented differences (p<0.05) in the following parameters: female (34.6% vs. 22%), mean age at symptom onset (25.0±9.2 years vs. 27.3 ± 10.0 years), disease duration (23 ± 13 years vs. 21 ± 12 years), uveitis (27.5% vs. 19.3%), presence of HLA-B27+ (93% vs. 83%), VAS for overall patient assessment (5.0 cm vs. 4.4 cm), BASDAI (4.4 cm vs. 4.0 cm) and response to NSAID (82% vs. 74%).
CONCLUSIONS: Patients with familial AS were younger at symptom onset and had poorer VAS for overall patient assessment and BASDAI than the other group. There was a higher prevalence of females, uveitis, positive HLA-B27, hip prostheses and a better response to NSAID in the familial AS group.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22011437

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

Review 1.  A registry of ankylosing spondylitis registries and prospects for global interfacing.

Authors:  John D Reveille
Journal:  Curr Opin Rheumatol       Date:  2013-07       Impact factor: 5.006

Review 2.  Ankylosing Spondylitis: HLA-B*27-Positive Versus HLA-B*27-Negative Disease.

Authors:  Nurullah Akkoç; Handan Yarkan; Gökçe Kenar; Muhammad A Khan
Journal:  Curr Rheumatol Rep       Date:  2017-05       Impact factor: 4.592

3.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

4.  Results from Polish Spondyloarthritis Initiative registry (PolSPI) - methodology and data from - the first year of observation.

Authors:  Zofia Guła; Tacjana Barczyńska; Marek Brzosko; Jerzy Gąsowski; Sławomir Jeka; Katarzyna Jodłowska-Cicio; Beata Kwaśny-Krochin; Piotr Leszczyński; Łukasz Lubiński; Katarzyna Łosińska; Katarzyna Pawlak-Buś; Hanna Przepiera-Będzak; Włodzimierz Samborski; Małgorzata Schlabs; Maciej Siedlar; Dorota Sikorska; Jerzy Świerkot; Małgorzata Węgierska; Piotr Wiland; Mariusz Korkosz
Journal:  Reumatologia       Date:  2017-04-28

5.  Phenotype difference between familial and sporadic ankylosing spondylitis in Korean patients.

Authors:  Hye Won Kim; Hye Rim Choe; Su Bin Lee; Won Ik Chang; Hyun Jun Chae; Jin Young Moon; Jisue Kang; Sungim Lee; Yeong Wook Song; Eun Young Lee
Journal:  J Korean Med Sci       Date:  2014-05-30       Impact factor: 2.153

6.  Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study.

Authors:  A Deodhar; V Strand; P G Conaghan; E Sullivan; S Blackburn; H Tian; K Gandhi; S M Jugl; R Alten
Journal:  BMC Rheumatol       Date:  2020-03-02

Review 7.  What Have We Learned From Family-Based Studies About Spondyloarthritis?

Authors:  Félicie Costantino; Hendrick Mambu Mambueni; Roula Said-Nahal; Henri-Jean Garchon; Maxime Breban
Journal:  Front Genet       Date:  2021-06-03       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.